Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones

Sánchez, José Elías García

doi:10.1093/jac/46.2.283

Cited by 73 publications

(55 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fluoroquinolones have in vitro activity against Hp (24). A recent in vitro study also showed a synergistic effect of quinolone antimicrobial agents and PPIs on strains of Hp (25).…”

Section: Discussionmentioning

confidence: 97%

Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia

Erçin¹,

Uygun²,

Toros³

et al. 2010

Turk J Gastroenterol

View full text Add to dashboard Cite

Helicobacter pylori (Hp) infection causes gastritis and gastroduodenal ulcer disease and is also associated with mucosa-associated lymphoid tissue (MALT) lymphoma and gastric cancer. In more than 20 years, researchers dealing with the eradication of this pathogen have been unable to find the ideal protocol, because the generally accepted minimum success rate of treatment regimens for Hp eradication is 80% (1, 2).The current standard first-line treatment to eradicate Hp is triple therapy, combining a proton pump inhibitor (PPI) with two antibiotics, mainly clarithromycin (500 mg b.i.d.) and amoxicillin (1 g b.i.d.) or metronidazole (500 mg b.i.d.), according Turk J Gastroenterol 2010; 21 (1): 12-16

show abstract

“…Fluoroquinolones have in vitro activity against Hp (24). A recent in vitro study also showed a synergistic effect of quinolone antimicrobial agents and PPIs on strains of Hp (25).…”

Section: Discussionmentioning

confidence: 97%

Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia

Erçin¹,

Uygun²,

Toros³

et al. 2010

Turk J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Furazolidone has also been proposed but it is associated with important adverse events too. 23 Fluoroquinolones have been shown in vitro to be actives drugs against H. pylori, 24 and different studies confirmed the efficacy of regimens containing levofloxacin as first-line treatment. 25,26 A recent in vitro study also showed a synergistic effect of quinolone antimicrobial agents and PPIs on 17 strains of H. pylori.…”

Section: Discussionmentioning

confidence: 97%

A 10‐day levofloxacin‐based triple therapy in patients who have failed two eradication courses

Gatta

Zullo

Perna

et al. 2005

Aliment Pharmacol Ther

109

View full text Add to dashboard Cite

Background: A standard third-line treatment is lacking, and European guidelines recommend performing culture in these patients. However, the use of this procedure as 'routine practice' is definitively not feasible. Aim: To evaluate the eradication rate of a 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses for Helicobacter pylori. Methods: A total of 151 patients with persistent Helicobacter pylori infection after two treatments were studied. Patients were considered positive if two of three endoscopic tests were positive. Susceptibility testing was also performed. Patients received a standard dose of

show abstract

“…Recently, some studies have evaluated the efficacy of new fluoroquinolones, such as levofloxacin, that could prove to be a valid alternative to standard antibiotics, not only as first-line therapies, but more interestingly, as second-line regimens [21,[88][89][90] . In this respect, levofloxacin-based second-line therapies represent an encouraging strategy for eradication failures, as some studies have demonstrated that levofloxacin has, in vitro, remarkable activity against H pylori [91] , and that primary resistances to such an antibiotic are (still) relatively infrequent (when compared with metronidazole or clarithromycin) [92][93][94][95][96] . A recent in vitro study also showed a synergistic effect of quinolone antimicrobial agents and PPIs on strains of H pylori [97] .…”

Section: Rbc Tetracycline and Metronidazolementioning

confidence: 99%

“Rescue” regimens after Helicobacter pylori treatment failure

Gisbert¹

2008

WJG

View full text Add to dashboard Cite

Helicobacter pylori (H pylori ) infection is the main cause of gastritis, gastroduodenal ulcer disease, and gastric cancer. After more than 20 years of experience in H pylori treatment, in my opinion, the ideal regimen to treat this infection is still to be found. Currently, apart from having to know first-line eradication regimens well, we must also be prepared to face treatment failures. Therefore, in designing a treatment strategy we should not focus on the results of primary therapy alone, but also on the final (overall) eradication rate. The choice of a "rescue" treatment depends on which treatment is used initially. If a clarithromycinbased regimen was used initially, a subsequent metronidazole-based treatment (quadruple therapy) may be used afterwards, and then a levofloxacinbased combination would be a third "rescue" option. Alternatively, it has recently been suggested that levofloxacin-based rescue therapy constitutes an encouraging second-line strategy, representing an alternative to quadruple therapy in patients with previous PPI-clarithromycin-amoxicillin failure, with the advantage of efficacy, simplicity and safety. In this case, a quadruple regimen may be reserved as a third-line rescue option. Finally, rifabutin-based rescue therapy constitutes an encouraging empirical fourthline strategy after multiple previous eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin. Even after two consecutive failures, several studies have demonstrated that H pylori eradication can finally be achieved in almost all patients if several rescue therapies are consecutively given. Therefore, the attitude in H pylori eradication therapy failure, even after two or more unsuccessful attempts, should be to fight and not to surrender.

show abstract

Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones

Cited by 73 publications

References 9 publications

Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia

Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia

A 10‐day levofloxacin‐based triple therapy in patients who have failed two eradication courses

“Rescue” regimens after Helicobacter pylori treatment failure

Contact Info

Product

Resources

About